Introduction {#Sec1}
============

Evidence based medicine \[EBM\] at bedside, a key healthcare quality measure, refers to the compendium for delivering optimum clinical care by balancing benefit-harm-costs. EBM involves appraisal, interpretation and implementation with adoption of beneficial interventions and de-adoption of interventions with potential harm.

***Our hypothesis from*** Niven et al \[[@CR1]\] where the reversal of intervention effect was not associated with timely de-adoption, is that for a rapid change in clinical practice perceived cost \[monetary or clinical harm\] attributable to the intervention must be high.

Tight glucose control \[TGC\] and corticosteroids are examples of nonproprietary and recombinant Activated protein C \[rt-APC\] an example of proprietary intervention with reversal of effect between publications, from benefit to harm. All three interventions were part of the Surviving Sepsis Campaign \[SSC\] EBM \[[@CR2]\].

Objectives {#Sec2}
==========

We explored the impact of reversal of intervention effect in septic shock trials on the adoption - de-adoption cycle of these three interventions; hypothesis being visible \'cost\' influences EBM.

Methods {#Sec3}
=======

Guy\'s and St. Thomas\' NHS Foundation Trust (London, England) is a 1,150-bed, University hospital with closed mixed medical and surgical ICUs and an early adopter of the SSC. Trained data collectors prospectively recorded all ICU admissions with severe sepsis/septic shock (SS) \[2005 to 2013\] into the SSC database. We report the adoption - de-adoption cycle of the interventions with effect reversal \[rt-APC, corticosteroids, TGC\] or unchanged (Antibiotics \< 3hours; lactate measurement \< 6 hours and lung protective ventilation \[LPV\]) over this period, relative to seminal publications for each intervention in septic shock patients. \[[@CR2]\] As an on-going hospital approved audit since inception, informed consent was waived. Data analysis was performed using Stata v13.1 (StataCorp, LP).

Results {#Sec4}
=======

N = 1,150 septic shock admissions. Compliance with intervention effect unchanged \[antibiotics, lactate measurement and LPV\] was high \[Figure [1](#Fig1){ref-type="fig"}a\]. Publication of CORTICUS \[[@CR3]\]trial reduced steroid use, whereas with the publication of PROWESS-SHOCK \[[@CR4]\] study alongside drug withdrawal stopped rt-APC use \[Figure [1](#Fig1){ref-type="fig"}b\]. Between the publications of Leuven-2 \[[@CR5]\] and NICE-SUGAR \[[@CR6]\] studies, the population average glucose values by quarter increased gradually from 5.7 to 7.6mmol/L, over the study period. This was associated with reduction in hypoglycemia incidence \[Figure [1](#Fig1){ref-type="fig"}c\].Figure 1**1a)No vs 1b) Reversal vs 1c) Blood Sugar.**

Conclusions {#Sec5}
===========

This descriptive analysis supports our hypothesis. Further analysis will identify key drivers for \'timely\' EBM beyond SSC bundle compliance.
